ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Smit, Marjon A, Maddalo, Gianluca, Greig, Kylie, Raaijmakers, Linsey M, Possik, Patricia A, van Breukelen, Bas, Cappadona, Salvatore, Heck, Albert JR, Altelaar, AF Maarten, Peeper, Daniel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300494/
https://www.ncbi.nlm.nih.gov/pubmed/25538140
http://dx.doi.org/10.15252/msb.20145450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300494/
https://www.ncbi.nlm.nih.gov/pubmed/25538140
http://dx.doi.org/10.15252/msb.20145450

Ejemplares similares